Why Farbe Firma is the Top Manufacturer of Piroxicam Injection
- Maulik Sudani
- 2 days ago
- 9 min read
Last Updated: June 30, 2026
TL;DR: Piroxicam Injection - a sterile aqueous solution of piroxicam, a potent oxicam (enolic-acid) NSAID and non-selective inhibitor of cyclo-oxygenase, supplied commonly as a 20 mg/mL solution in a 1 mL or 2 mL ampoule given by deep intramuscular injection - is the long-acting, non-opioid analgesic and anti-inflammatory clinicians use for the short-term management of acute musculoskeletal pain, acute gout and painful exacerbations of rheumatic disease, where piroxicam's distinctively long elimination half-life supports once-daily dosing. Because piroxicam is a poorly water-soluble, markedly light-sensitive yellow active that must be held in solution by a carefully designed solubilising system, each ampoule must deliver an exact, sterile, particulate-free dose at the labelled strength, with the stability-indicating assay, the related-substance profile, robust photostability and light protection, the controlled pH, clarity, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Piroxicam Injection at our Gujarat, India facility and supplies it to surgical, rheumatology, pain-management and hospital-pharmacy services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Oxicam (enolic-acid) NSAID and non-selective cyclo-oxygenase inhibitor - piroxicam blocks prostaglandin synthesis to control pain and inflammation, and Piroxicam Injection (20 mg/mL, deep intramuscular) has a distinctively long half-life that supports once-daily dosing and demands an exact, reproducible parenteral dose for the short-term management of acute musculoskeletal and rheumatic pain and acute gout.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated light-protected compounding and amber-ampoule filling lines, control of the stability-indicating assay, the related-substance profile, the solubilising system, robust photostability, the controlled pH, clarity, fill volume, particulate and endotoxin, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, stability-indicating method-validation data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution ampoule and vial contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Piroxicam Injection Demands a Premium Manufacturer
Piroxicam Injection holds a long-established place in acute-pain, rheumatology and inflammatory-disease practice across every market. It is the analgesic and anti-inflammatory a clinician reaches for when a patient needs strong, non-opioid relief from acute musculoskeletal pain, an episode of acute gout or a painful exacerbation of rheumatoid arthritis or osteoarthritis but cannot conveniently take a tablet. What makes piroxicam distinctive among the NSAIDs is its pharmacokinetics: it is one of the original oxicams, an enolic-acid, non-selective inhibitor of both cyclo-oxygenase-1 and cyclo-oxygenase-2, and it has a notably long elimination half-life - on the order of a day or more - so a single daily dose can maintain steady analgesic and anti-inflammatory cover. That long-acting profile is exactly why piroxicam remains a valued option for sustained pain relief within a multimodal, opioid-sparing approach wherever a dependable, long-acting non-opioid agent is required. Because the injection is given parenterally, the dose from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, since the prescriber depends on a precise, ready, reproducible parenteral dose.
That clinical reality places real demands on the manufacturer. Piroxicam Injection is presented as a ready-to-use sterile solution - for example 20 mg of piroxicam in a 1 mL or 2 mL ampoule, 20 mg/mL, given by deep intramuscular injection - so the assay must be exact and the fill volume accurate so that each unit delivers the labelled content. The defining formulation challenge is that piroxicam is poorly water-soluble and is a markedly light-sensitive yellow active, so the bulk solution depends on a carefully designed solubilising system - typically a co-solvent or buffering base that holds piroxicam fully in solution at a controlled pH - and robust photostability under ICH Q1B, light-protective processing and amber-glass or otherwise light-resistant packaging are genuine critical quality attributes rather than afterthoughts. The solution must stay clear, free of visible and sub-visible particulates and low in endotoxin, and the manufacturer must run a stability-indicating method that resolves and quantifies piroxicam and its related and photodegradation substances without interference. The right sterilisation route - terminal moist-heat where the formulation and container qualify, otherwise full aseptic processing - must be selected and validated. The NSAID class cautions - the gastrointestinal, renal and cardiovascular thrombotic risks, the risk of serious skin reactions and of hypersensitivity and bronchospasm, and photosensitivity reactions - must be clearly carried on the label, and piroxicam's long half-life makes the accuracy of each dose and the avoidance of accumulation especially important. Choosing a Piroxicam Injection manufacturer that treats the solubilising system, photostability, the stability-indicating assay, related-substance control, the controlled pH, and clarity and particulate and endotoxin control as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Piroxicam Injection Manufacturer Apart
A world-class manufacturer of Piroxicam Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of piroxicam with related-substance control by validated HPLC, which a potent, photolabile, poorly-soluble NSAID demands; a robust, validated sterilisation and fill process built around a solubilised, light-protected solution that must stay clear and precipitate-free from compounding through to the point of use; and tender-ready dossier support, including the all-important photostability and accelerated stability data, for an analgesic procured through hospital-pharmacy and ministry-of-health channels. It starts with the active - pharmacopoeial-grade piroxicam sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production. Because the entire value of the product depends on the poorly-soluble active staying fully dissolved and surviving manufacture, storage and use without photodegrading, the solubilisation and photostability data are treated as central evidence rather than supporting annexes.
Compounding and filling then have to defend the assay, the clarity and, above all, the dissolved state and photostability of a poorly-soluble, markedly light-sensitive active. The bulk solution is compounded in water-for-injection with the solubilising system at the controlled pH that holds piroxicam fully in solution, sterile-filtered through a 0.22 micron membrane and filled into amber ampoules - or vials - under ISO Class 5 conditions and under strict light protection, with the validated sterilisation route locked in the master batch record. Filled units are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of piroxicam by validated HPLC, the related-substance profile, solution pH, deliverable (fill) volume, visible and sub-visible particulate matter, and that endotoxin is held well within limits so the solution is safe for deep intramuscular administration. Because the active is poorly soluble and markedly light-sensitive, assay accuracy, related-substance control, pH control and photostability are confirmed together, and light protection is maintained from compounding through filling to final packaging so the assay and clarity stay within specification across shelf life, with no precipitation and no photodegradation in the ampoule.
Quality Systems Behind Every Piroxicam Injection
Every Farbe Firma Piroxicam Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of piroxicam against pharmacopoeial reference standards, control of related and photodegradation substances by HPLC, solution pH, clarity and colour of the solution, deliverable (fill) volume, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule or vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release. Where the marketed presentation uses amber glass, the protective effect of the container itself is qualified as part of the overall light-protection strategy rather than simply assumed.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated filling lines with 100 % inspection, light-protected compounding and holding, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because piroxicam is a potent, poorly-soluble, markedly light-sensitive NSAID given parenterally and the assay, related-substance profile, pH and photostability drive both efficacy and safety, we treat the stability-indicating assay, the related-substance profile, the controlled pH and the deliverable volume as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under ICH Q1A long-term and accelerated (40 degrees C / 75 % RH) conditions, with ICH Q1B photostability documented in detail, so the assay, clarity and colour stay within specification across the labelled shelf life.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Piroxicam Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad analgesia, anti-inflammatory, rheumatology and peri-operative small-volume parenteral portfolio. For Piroxicam Injection specifically, we supply the ready-to-use 20 mg/mL solution in amber-ampoule and vial presentations under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier - including the solubilisation, stability-indicating-assay, related-substance, pH, photostability, sterilisation and container-closure data package - ready to hand for registration and tender qualification. Buyers evaluating Piroxicam Injection can request the photostability and accelerated-stability summaries up front, which is often the deciding technical evidence for a photolabile, poorly-soluble NSAID in hospital-formulary and ministry-of-health review.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, translated package inserts and artwork - including deep-intramuscular administration instructions, store-below-25-degrees-C and protect-from-light storage directions, and the gastrointestinal, renal, cardiovascular, serious-skin-reaction, hypersensitivity-and-bronchospasm and photosensitivity cautions of the NSAID class - for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Piroxicam Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment schedule delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team - practising pharmacists and R&D scientists - can talk through API sourcing, the design of a solubilising system for a poorly-soluble oxicam, the development of a stability-indicating assay, related-substance and photodegradation control, controlled-pH formulation design, light-protection and photostability strategy, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose accuracy, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a poorly-soluble, markedly light-sensitive NSAID where the solubilising system, photostability and dose precision directly govern patient safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Piroxicam Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Piroxicam Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, validated water-for-injection systems, dedicated light-protected compounding and amber-ampoule filling lines, validated sterilisation, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Piroxicam Injection do you supply?
Our standard presentation is the ready-to-use 20 mg/mL solution of piroxicam in a 1 mL or 2 mL amber ampoule for deep intramuscular injection. Custom strengths, fill configurations, ampoule and vial formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Piroxicam Injection mainly used for?
Piroxicam Injection is used for the short-term management of acute musculoskeletal and rheumatic pain, acute gout and painful exacerbations of rheumatoid arthritis and osteoarthritis, when an oral dose is not practical. It is a potent oxicam (enolic-acid) NSAID and non-selective cyclo-oxygenase inhibitor with a distinctively long half-life that supports once-daily dosing; Farbe Firma verifies the assay, related-substance profile, pH, clarity, deliverable volume, particulate matter and endotoxin at release so each ampoule delivers a precise, reproducible dose. It is given by deep intramuscular injection, and the gastrointestinal, renal, cardiovascular, serious-skin-reaction, hypersensitivity and photosensitivity cautions of the class are carried on the label.
Can Farbe Firma support country-specific registrations for Piroxicam Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, stability-indicating method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Piroxicam Injection contract manufacturing?
MOQs vary by strength, ampoule or vial size, sterilisation route, label complexity and dossier requirements. For our analgesia and anti-inflammatory small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments